Abstract
Novel and innovative treatment options for atopic dermatitis (AD) are underway. The recent advancements in understanding AD are reminiscent of the progress made in psoriasis research over a decade ago.
Disclosure statement
Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron.
Dr. Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma and Janssen Pharmaceuticals.
Dr. Thyssen is supported by an unrestricted grant from the Lundbeck Foundation and has attended an advisory board for Roche and Sanofi-Genzyme, and been a speaker on atopic dermatitis for LEO Pharma.
Mr. No and Ms. Amin do not have any potential conflicts of interest to report.